Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy ; volume:69 ; number:1 ; day:27 ; month:11 ; year:2019 ; pages:159-161 ; date:1.2020
Cancer immunology immunotherapy ; 69, Heft 1 (27.11.2019), 159-161, 1.2020
- Urheber
-
Mensali, Nadia
Myhre, Marit Renée
Dillard, Pierre
Pollmann, Sylvie
Gaudernack, Gustav
Kvalheim, Gunnar
Wälchli, Sébastien
Inderberg, Else Marit
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-019-02409-6
- URN
-
urn:nbn:de:101:1-2020041406492526355397
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mensali, Nadia
- Myhre, Marit Renée
- Dillard, Pierre
- Pollmann, Sylvie
- Gaudernack, Gustav
- Kvalheim, Gunnar
- Wälchli, Sébastien
- Inderberg, Else Marit
- SpringerLink (Online service)
Ähnliche Objekte (12)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
TCR engineered T cells for solid tumor immunotherapy
TCR-like antibodies in cancer immunotherapy
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
TCR diversity – a universal cancer immunotherapy biomarker?
Next-Generation TCR-transgenic T cells for Immunotherapy
Imaging of tumour response to immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
HNSCC: tumour antigens and their targeting by immunotherapy
Combining effects of one tumor-stroma recognizing TCR with one cancer‑cell specific TCR for eradication of solid tumors
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
TCR engineered T cells for solid tumor immunotherapy
TCR-like antibodies in cancer immunotherapy
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
TCR diversity – a universal cancer immunotherapy biomarker?
Next-Generation TCR-transgenic T cells for Immunotherapy
Imaging of tumour response to immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
HNSCC: tumour antigens and their targeting by immunotherapy
Combining effects of one tumor-stroma recognizing TCR with one cancer‑cell specific TCR for eradication of solid tumors
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
TCR engineered T cells for solid tumor immunotherapy
TCR-like antibodies in cancer immunotherapy
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
TCR diversity – a universal cancer immunotherapy biomarker?
Next-Generation TCR-transgenic T cells for Immunotherapy
Imaging of tumour response to immunotherapy
RNAi-mediated knockdown of the endogenous TCR improves safety of immunotherapy with TCR gene-modified T cells
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
HNSCC: tumour antigens and their targeting by immunotherapy